✦ LIBER ✦

Efficacy of combination therapy of antiviral and immunosuppressive drugs for the treatment of severe acute exacerbation of chronic hepatitis B

✍ Scribed by Keiichi Fujiwara; Shin Yasui; Yutaka Yonemitsu; Kenichi Fukai; Makoto Arai; Fumio Imazeki; Akihiro Suzuki; Hiroshi Suzuki; Tomohito Sadahiro; Shigeto Oda; Osamu Yokosuka

Publisher: Springer Japan
Year: 2008
Tongue: English
Weight: 381 KB
Volume: 43
Category: Article
ISSN: 0944-1174
DOI: 10.1007/s00535-008-2222-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The requirement for a sufficient period

The requirement for a sufficient period of corticosteroid treatment in combination with nucleoside analogue for severe acute exacerbation of chronic hepatitis B

✍ Keiichi Fujiwara; Shin Yasui; Koichiro Okitsu; Yutaka Yonemitsu; Shigeto Oda; Os 📂 Article 📅 2010 🏛 Springer Japan 🌐 English ⚖ 248 KB

The ethics of placebo treatment for pati

The ethics of placebo treatment for patients with acute exacerbation of chronic hepatitis B

✍ Gin-Ho Lo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 320 KB

I can hardly share the passionate enthusiasm of Breuhahn et al. for the ''dramatic'' improvements in understanding of molecular pathogenesis of hepatocellular carcinoma (HCC) and the claim for ''further rationally designed clinical trials based on molecular evidence''. 1 Among the causes of HCC, the

Severe acute exacerbation of liver disea

Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B

✍ Akihito Tsubota; Yasuji Arase; Fumitaka Suzuki; Mariko Kobayashi; Marie Matsuda; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

## Abstract The pretherapy factors that could influence the emergence of resistant hepatitis B virus (HBV) tyrosine‐methionine‐aspartate‐aspartate (YMDD) motif mutants against lamivudine are not fully known in prolonged lamivudine therapy for hepatitis B e antigen (HBeAg)‐positive chronic hepatitis

Efficacy and tolerability of long-term t

Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B

✍ Luiz Caetano Da Silva; João Renato Rebello Pinho; Roberta Sitnik; Luís Edmundo P 📂 Article 📅 2001 🏛 Springer Japan 🌐 English ⚖ 158 KB

Long-term efficacy and safety of adefovi

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen–positive chronic hepatitis B

✍ Patrick Marcellin; Ting-Tsung Chang; Seng G. Lee Lim; William Sievert; Myron Ton 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 277 KB 👁 1 views

Treatment of 171 patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) with adefovir dipivoxil (ADV) 10 mg over 48 weeks resulted in significant histological, virological, serological, and biochemical improvement compared with placebo. The long-term efficacy and safety of AD

Antiviral efficacy of combination therap

Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance

✍ Hyo-Joon Yang; Jeong-Hoon Lee; Yoon Jun Kim; Jung-Hwan Yoon; Hyo-Suk Lee 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB

## Abstract There is little clinical information on the management of hepatitis B virus (HBV) that is resistant to multiple drugs including entecavir (ETV). The present retrospective cohort study assessed the antiviral efficacy of ETV/adefovir dipivoxil (ADV) combination therapy for ETV‐resistant H